Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand the safety and estimate the efficacy of combining
anti-CD3 x anti-SLAMF7 bispecific antibody armed activated T cells (SLAMF7 BATs/CS1 BATs) for
patients with relapsed and/or refractory multiple myeloma. Patients receive 4 weekly doses
and then 4 more doses every 2 weeks of SLAMF7 BATs by intravenous infusion. If patients have
at least stable disease after these infusions, then they may receive additional infusions
every 4 weeks up to a maximum of 21 infusions (including the initial 8 infusions).